Functional Recovery After Wharton’s Jelly-Derived Mesenchymal Stem Cell Administration in a Patient with Traumatic Brain Injury: A Pilot Study

3Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

AIM: To introduce a traumatic brain injury (TBI) patient who underwent stem cell transplantation (SCT) in order to minimize the remaining injury deficiencies. MATERIAL and METHODS: This study included a 29 years old male who had TBI resulting from a vehicle accident which took place one and a half years ago. The participant received six doses of intrathecal, intramuscular, and intravenous transplantation of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) at a goal dose of 1xI06/ kg respectively for each route of administration for six months. RESULTS: No important negative effects were reported. The patients’ speech, cognitive, memory and fine motor skills were improved. The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG). CONCLUSION: SCT can have a promising future as a medical approach in recurrent TBI.

Cite

CITATION STYLE

APA

KABATAS, S., CIVELEK, E., SEZEN, G. B., KAPLAN, N., SAVRUNLU, E. C., CETIN, E., … KARAOZ, E. (2020). Functional Recovery After Wharton’s Jelly-Derived Mesenchymal Stem Cell Administration in a Patient with Traumatic Brain Injury: A Pilot Study. Turkish Neurosurgery, 30(6), 914–922. https://doi.org/10.5137/1019-5149.JTN.31732-20.1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free